2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular …
N Marx, M Federici, K Schütt… - European heart …, 2023 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association
BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia
This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
good for the greatest number of people with familial hypercholesterolaemia (FH) across …
Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients
Importance The effects of bempedoic acid on cardiovascular outcomes in statin-intolerant
patients without a prior cardiovascular event (primary prevention) have not been fully …
patients without a prior cardiovascular event (primary prevention) have not been fully …
[HTML][HTML] Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
E Raschi, M Casula, AFG Cicero, A Corsini… - Pharmacology & …, 2023 - Elsevier
The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
J Brandts, KK Ray - Nature Reviews Cardiology, 2023 - nature.com
Lowering the levels of LDL cholesterol in the plasma has been shown to reduce the risk of
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
atherosclerotic cardiovascular disease (ASCVD). Several other lipoproteins, such as …
[HTML][HTML] Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP)
Cardiovascular disease (CVD) is a chronic non-communicable disease (NCD) and the
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
predominant cause of morbidity and mortality worldwide. Substantial reductions in the CVD …
Inflammation in acute myocardial infarction: the good, the bad and the ugly
Convergent experimental and clinical evidence have established the pathophysiological
importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in …
importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in …
Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention
Despite treatment with statins, patients with elevated low-density lipoprotein cholesterol
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …
(LDL-C) and triglycerides remain at increased risk for adverse cardiovascular events …
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial
KK Ray, SJ Nicholls, N Li, MJ Louie… - The Lancet Diabetes & …, 2024 - thelancet.com
Background Statins reduce LDL cholesterol and cardiovascular events among those with or
without diabetes but have been reported to increase new-onset diabetes. The CLEAR …
without diabetes but have been reported to increase new-onset diabetes. The CLEAR …